LEVOLET - (0.075MG,0.088MG,0.1MG,0.112MG,0.125MG,0.137MG,0.15MG,0.175MG,0.2MG,0.3MG ; Tablet)

Generic Name	LEVOTHYROXINE SODIUM	**Innovator**	Genus Life
Dosage	0.075MG,0.088MG,0.1MG,0.112MG,0.125MG,0.137MG,0.15MG,0.175MG,0.2MG,0.3MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	LEVOLET is levothyroxine sodium (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.